Protein molecule may offer method for treating untreatable cancers

January 22, 2014 by Mattie Bekink

The effective treatment of cancer requires the ability to destroy cancerous cells. Nearly one-third of all cancers today involve mutations of the Kras gene, which has proven resistant to existing cancer treatments. The current prognosis for patients with mutant Kras cancers is poor because there is no effective treatment. However, recent analysis by Valerie Wells of NYU London and Livio Mallucci of King's College London may present a new method to combat these untreatable cancers.

In a feature article in Drug Discovery Today, Wells and Mallucci discuss the current therapeutic strategies and their limitations, highlighting a new way forward using the recombinant form of a physiological protein molecule, beta-GBP, which has proven to be effective against human Kras-driven tumors in animal models.

There are several significant aspects to their discovery. First, the beta-GBP molecule they have identified kills mutant Kras and other cancer cells by activating alternative routes to destroy cancer while leaving normal cells unharmed. Second, the beta-GBP molecule is naturally occurring in the body and therefore would avoid the complexity of current combinatorial therapies and the issues of drug resistance, toxicity and all side effects experienced with chemotherapy. Finally, translation of beta-GBP to the clinic, facilitated by its physiological nature, could open a new therapeutic opportunity representing a significant step forward in the treatment of cancers resistant to all current methods.

More information: Livio Mallucci, Valerie Wells, "The end of KRAS and other cancers? A new way forward." Drug Discovery Today, Available online 27 November 2013, ISSN 1359-6446, dx.doi.org/10.1016/j.drudis.2013.11.018.

Related Stories

Combination therapies for drug-resistant cancers

October 10, 2011

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.